Kornimate/medical-research-clean huggingface dataset:
evaluation of pupil dilation speed with the map dispenser

Conditions: Mydriasis

Summary: 1 mist or 2 mists of the study drug will be administered to both eyes according to a pre-specified randomization plan to determine the effect on pupil dilation

after screening, eligible subjects will be scheduled for 2 treatment visits where either 1 mist or 2 mists of the study drug will be administered to both eyes according to a pre-specified randomization plan. safety evaluations and efficacy measurements will be performed at specified time intervals thereafter. pupil dilation for each treatment will be compared at each time interval.

Eligibility criteria:
inclusion criteria: 1. photopic screening pupil diameter ≤ 3.5 mm in each eye exclusion criteria: 1. allergy to phenylephrine hydrochloride, tropicamide, or benzalkonium chloride. 2. use of benzodiazepines, monoamine oxidase inhibitors, tricyclic antidepressants, anticonvulsants, cholinergic drug at screening or anticipated during the study period. 3. history of closed-angle glaucoma. 4. anatomically narrow anterior chamber angles (van herrick grade ≤ 2 in either eye). 5. ocular surgery or laser treatment of any kind prior to the screening visit. 6. history of iris trauma, surgery, or atrophy. 7. irregularly-shaped pupil secondary to ocular trauma or congenital defect, or history of neurogenic pupil disorder.
postoperative complication after g.a

Conditions: Complication of Anesthesia

Summary: what are the possible postoperative complications that may occur for children following dental treatment under general anaesthesia and is there a correlation between those complications and type of dental treatment done?

nowadays, early childhood caries (ecc) remains a significant challenge of public health in egyptian children. in most cases, children with ecc could accept dental treatment under non-pharmacological behavior management or sedation. however, some very young children or those suffering severe anxiety, mental or physical disabilities, could only be treated under dental general anesthesia (dga). dental general anesthesia (dga) is a safe and high-quality restorative and preventive treatment option for children with severe early childhood caries (s-ecc), who require extensive dental treatment and exhibit anxiety and emotional or cognitive immaturity or are medically compromised. however, several postoperative complications have been reported in children under dga in many studies. for a day-stay, general anesthesia procedure to be an acceptable option, care during and after surgery must be of the highest quality, and postoperative complications must be minimized.

Eligibility criteria:
inclusion criteria: 1. children with age range from 3 to 6 years old . 2. children affected by dental caries in more than 4 primary teeth. 3. uncooperative child indicated for treatment under g.a 4. classified by american society of anaesthesiologists physical status as class 1 5. parents accepted to participate and willing to sign an informed consent. exclusion criteria: * 1) the children whose guardians or caregivers have a problem in communicating with the medical staff
"all comers" post market clinical follow-up (pmcf) with multi-loc for flow limiting outcomes (locomotive extended)

Conditions: Peripheral Arterial Occlusive Disease

Summary: the aim of the study is to assess the safety and efficacy of the multi-loc® peripheral stent system to treat de novo and restenotic lesions (no in-stent restenosis (isr), no restenosis post drug coated balloon (dcb) after flow limiting plain old balloon angioplasty (poba) and/or dcb dilatations in the superficial femoral artery (sfa) and popliteal segments (p1, p2 \& p3)

this study is an non-randomized, prospective, multi-center, non-interventional study (registry, for germany: §23b mpg)

Eligibility criteria:
inclusion criteria: * willingness to treat flow-limiting dissections/recoil after plain old balloon angioplasty (poba)/drug coated balloon (dcb) interventions * patients in rutherford classes 2 through 5 * patients eligible for peripheral revascularization by means of percutaneous transluminal angioplasty (pta) and stenting * patients must be at least 18 years of age * patient with a life expectance of at least 12 months * patients who are mentally and linguistically able to understand the aim of the study and to show sufficient compliance in the following study protocol * patients must agree to undergo at least the 6-month clinical follow-up * patient is able to verbally acknowledge an understanding of the associated risks, benefits, and treatment alternatives to therapeutic options of this trial, e.g. balloon angioplasty by means of other suitable stent devices. patients, by providing their informed consent, agree to these risks and benefits as stated in the patient informed consent document. * lesions with unsatisfying angiographic results due to recoil and/or dissections after poba/dcb interventions * infra-inguinal lesions in the superficial femoral artery (sfa) and popliteal segments (p1,p2 \& p3) reference vessel diameters between 4 and 7.0 mm, lesion length suitable for the release of at least 2 stent (up to 6) segments implanted with a minimum inter-stent distance of 1 cm * diameter stenosis pre-procedure must be larger or equal to 70% * vessels must have adequate distal run-off with at least one vessel to the foot or with collaterals in the calf supplying sufficient flow to the foot. (lesions separated by less than 2 cm are considered as one lesion) exclusion criteria: * patient not suitable for revascularization by interventional means
eval. of safety and effectiveness of the fmwand ferromagnetic surgical system during total mesorectal excision surgery

Conditions: Colorectal Cancer

Summary: the objective of the clinical trial is to determine the suitability of the fmwand ferromagnetic surgical system for total mesorectal excision surgery.


Eligibility criteria:
inclusion criteria: * confirmed rectal cancer to the lower two-thirds of the rectum (higher and t2 n0 or n+) * amenable for standard surgery procedures using electrocautery, argon beam, lasers or other conventional tissue removal modalities * ecog status ≤ 2 * life expectancy \>3 months * age ≥ 18 years old * age ≤ 80 years old * ability to provide written informed consent and hipaa forms prior to admission to this study * willingness to meet all of the expected requirements of this clinical protocol exclusion criteria: * patient with metastasis * history of radiotherapy or chemotherapy for the treatment of rectal cancer * uremia - bun\>40 * hemodialysis * existing urinary or fecal incontinence * pregnant or lactating * previously diagnosed coagulopathy or bleeding diathesis * currently, or within the previous 10 days prior to surgery, taking any medications that would produce bleeding diathesis including but not limited to, plavix, warfarin, nsaids, clopidogrel, ticlopidine or valproic acid * history of significant cardiac disorders that would necessitate special fluid management protocols * history of acute myocardial infarction and/or acute angina * inr \>1.4 in the 24 hours prior to surgery * ptt \>40 in the 24 hours prior to surgery * platelet count \<100k in the 24 hours prior to surgery
dietary intakes and periodontal health: a follow-up study

Conditions: Periodontal Attachment Loss; Periodontal Pocket

Summary: a previous study, on which this study is based, found that a diet higher in fruits and vegetables, beta-carotene, vitamin c, alpha-tocopherol, and fish oils (specifically eicosapentaenoic acid (epa) and docosahexaenoic acid (dha)) was positively associated with periodontal healing after sanative therapy (nct02291835). the investigator's next step, in the present study, is to determine long-term benefits of sanative therapy in which patients have regular maintenance hygiene cleanings on periodontal health. specifically, the relationship between intakes of specific foods, nutrients and supplements with clinical periodontal outcomes will be studied.

periodontitis is a chronic oral infection that results in the breakdown of connective tissue and alveolar bone that support the teeth. bacteria and the body's own immune system mediate the severity of periodontitis, where teeth may become loose, fall out or have to be removed. sanative therapy is a non-surgical process involving mechanical debridement of bacterial biofilms on roots of teeth, below the gum line. participants in this present study previously underwent sanative therapy several years ago and have been attending the clinic for regular maintenance appointments to maintain periodontal health. while significant associations were observed with higher intakes of fruits and vegetables and specific nutrients (vitamins c and e, beta-carotene, fish oils) within a few months after sanative therapy, this study will follow-up these findings to determine if such relationships persist during a period of relatively stable periodontal health. given new insights into a potential role of flavonoids in maintaining periodontal health, this aspect will also be studied. the overall objective is to determine if higher intakes of foods, nutrients and supplements known to have osteogenic and immunomodulatory effects are associated with improved clinical outcomes in individuals who previously underwent sanative therapy. at the regular maintenance appointment, clinical measures will be evaluated (clinical attachment loss, probing depth, bleeding on probing, plaque index). as well, the following will be evaluated: dietary intakes of macronutrients and micronutrients using the block 2015 food frequency questionnaire; intakes of fruit, vegetables and fiber using the block dietary fruit-vegetable-fiber screener; nutritional supplement use and tea intake using specially developed questionnaires and salivary markers of inflammation using biochemical assays.

Eligibility criteria:
inclusion criteria: * previously participated in the original study (nct02291835) exclusion criteria: * under 19 years of age * have not participated in the previous study as this study is a direct follow-up of those participants

Keywords: dietary intake nutritional supplements sanative therapy healing flavonoids tea
bradykinin receptor blocker in ace inhibitor-associated angioedema

Conditions: Angioneurotic Edema

Summary: individuals with heart disease or high blood pressure are often prescribed angiotensin converting enzyme (ace) inhibitors to treat their disease. however, the use of ace inhibitors can be associated with angioedema, a rare but life-threatening condition that causes swelling of the face and other body parts. this study will evaluate the effectiveness of the drug hoe-140 at decreasing symptoms of angioedema in people taking ace inhibitors who develop the condition.

people who take ace inhibitors may develop angioedema, a condition that causes itchy and painful swelling beneath the skin around the eyes, lips, tongue, throat, hands, or feet. in severe cases, the throat may swell, obstructing the airway and leading to breathing difficulty. ace inhibitors prevent the breakdown of a natural chemical in the body called bradykinin. increased levels of bradykinin, which can cause swelling, may contribute to the development of angioedema. blocking bradykinin receptor cells prevents bradykinin from initiating swelling and may lead to a possible decrease in angioedema symptoms. the purpose of this study is to evaluate the effectiveness of hoe-140, a bradykinin receptor blocker, at reducing symptoms in people with ace inhibitor-associated angioedema. this study will enroll people admitted to the emergency room or hospital who have a severe case of ace inhibitor-associated angioedema. participants will be randomly assigned to receive an injection of either hoe-140 or placebo. initially, participants will undergo an electrocardiogram to measure the electrical activity of the heart. then blood pressure measurements, blood collection, a physical exam to determine the extent and duration of swelling, and photographs of the swelling will occur at 2, 4, 8, 16, and 24 hours following the start of treatment. questionnaires will be completed by study staff and participants to assess changes in angioedema symptoms and the extent of swelling. participants will remain in the hospital for 24 to 48 hours, depending on the severity of their symptoms. blood will be collected at a follow-up visit that will occur 7 days after the resolution of angioedema symptoms.

Eligibility criteria:
inclusion criteria: * ambulatory * ace inhibitor-associated angioedema, as defined as swelling of the lips, pharynx, or face while taking an ace inhibitor, no history of angioedema while not taking an ace inhibitor, and no evidence of abnormal c1 inhibitor concentration or abnormal complement levels. people with possible cases of ace inhibitor-associated bowel edema will not be enrolled. * if female, must be postmenopausal for at least 1 year prior to study entry, undergone surgical sterilization, or willing to use an effective form of birth control and take a pregnancy test daily for the duration of the study exclusion criteria: * pregnant or breastfeeding * started taking birth control pills in the 6 months prior to study entry

Keywords: ace inhibitor angioedema bradykinin swelling
precise treatment system of biliary malignancies based on special disease database

Conditions: Cholangiocarcinoma; Gall Bladder Carcinoma; Biliary System Disorder

Summary: malignant tumors of biliary system lack standard treatment and precise prognosis assessment methods. this study including 12 hospitals, collecting clinical and follow-up data of patients with biliary malignant tumors including cholangiocarcinoma and gallbladder carcinoma in recent 10 years, aim to build a special disease database, then use bayesian networks and importance theory to establish a mathematical model to assess treatment strategies and prognosis accurately. at the same time, data on biliary malignant tumors newly treated by multicenters from 2018 to 2020 will be included to validate, adjust and refine the models to guide clinical individualized precise treatment.


Eligibility criteria:
inclusion criteria： * clinical diagnosis of biliary malignancy including gallbladder carcinoma or cholangiocarcinoma verified by pathological results * must be able to undergo surgery * undergoing radical surgery for biliary malignancy (r0 or r1 resection) * not complicated with other malignancy * no other treatments before and during surgery, such as radiotherapy and chemotherapy. exclusion criteria: * non-primary gallbladder or cholangiocarcinoma * with distant metastasis (m1 phase) * incomplete follow-up data * died within 30 days after surgery.

Keywords: prognosis surgery options bayesian networks
hepatitis b seroepidemiology among young adults

Conditions: Hepatitis B

Summary: taiwan has launched a successful nationwide neonatal hepatitis b immunization since july 1, 1984. it successfully decreased the incidence of hepatitis b virus infection, the hepatitis b carrier rate as well as liver diseases among children and adolescents. the sexual transmission route is another important way of hepatitis b infection aside from the mother and child vertical infection, especially for youth and adults. hepatitis b vaccination cohort refers to those who were born after 1986 and received hepatitis b vaccine immunization during newborn period. they are gradually entering into young adults and adolescent age. among them, there is no empirical evidence to show the actual infection rate and to help implement hepatitis b vaccine booster policy for those who had three seronegative viral markers of hepatitis b. therefore, the study design is to collect three consecutive years graduate school students school entry health examination data and undergo three hepatitis b viral markers checkup and blood types. the data linkage includes their health checkup data in the freshmen period, taiwan cdc databank for neonatal hepatitis b immunization records, pregnancy and birth record registry, taiwan cancer registry and taiwan death record registry.

this study is aimed to delineate the hepatitis b seroepidemiology among young adults with or without neonatal hepatitis b immunization, among young adults with hepatitis b booster in the university period, among the mothers of hepatitis b vaccination cohort. the results of this study will provide important information to help government implement hepatitis b vaccine booster policy in the adolescents and young adults.

Eligibility criteria:
inclusion criteria: * young adults 20 to 30 years old. exclusion criteria: * refused to undergo blood draw or questionaire.

Keywords: hepatitis b epidemiology youth vaccine
effect of liraglutide or exenatide added to an ongoing treatment on blood glucose control in subjects with type 2 diabetes

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: this trial is conducted in europe and the united states of america (usa). the aim of this trial is to compare the effect on glycaemic control of liraglutide or exenatide when added to subject's ongoing oad (oral anti-diabetic drug) treatment of either metformin, sulphonylurea or a combination of both in subjects with type 2 diabetes. two trial periods: a 26 week randomised, followed by a 52 week extension (14 + 38 weeks) where all subjects received liraglutide + oad after previous randomisation to either liraglutide or exenatide, both combined with oad treatment.


Eligibility criteria:
inclusion criteria: * type 2 diabetes * stable treatment with oral anti-diabetic drugs (metformin, sulphonylurea or a combination of both) for at least 3 months at the discretion of the investigator * hba1c equal to or greater than 7.0% and equal to or lower than 11.0% * body mass index (bmi) equal to or lower than 45.0 kg/m2 exclusion criteria: * previous treatment with insulin * treatment with any anti-diabetic drug other than metformin and sulphonylurea * any previous exposure to exenatide or liraglutide * impaired liver or/and renal function * history of any significant cardiac events * known retinopathy or maculopathy requiring acute treatment * recurrent major hypoglycaemia or hypoglycaemic unawareness
transcranial stimulation and motor training in stroke rehabilitation

Conditions: Stroke; Cerebral Infarction; Cerebrovascular Disorders; Brain Diseases

Summary: this study aims to test whether repeated sessions of tdcs result in long-lasting improvements in motor function in patients with chronic stroke.

previous research that utilises single sessions of tdcs have demonstrated functional improvements; however, these improvements are usually short-lived, lasting less than one hour before the patient's performance returns to baseline. it has been suggested that repeated stimulation sessions are required to elicit long-lasting improvements. we aim to consider these details over the duration of this research, during which patients with chronic stroke will attend for 16 sessions over the course of 3 months. this research has important implications; previous studies suggest that such an approach has the potential to facilitate physical rehabilitation post-stroke and establish tdcs as a clinically viable rehabilitative tool. recovery of motor skills may take many months to acquire and therefore strategies that have the potential to enhance acquisition of skill are of practical and scientific interest.

Eligibility criteria:
inclusion criteria: * participant is willing and able to give informed consent for participation in the study. * male or female, aged 18 - 80 years. * patients should be at least six months post first symptomatic stroke affecting motor function of the hand. exclusion criteria: * anyone who does not have adequate understanding of verbal and written information in english, sufficient to complete any of the safety screening forms. * anyone who has a previous history of epilepsy, febrile convulsions as a child or recurrent fainting fits. likewise, anyone who has a significant family history of epilepsy would be excluded as all these conditions carry a theoretical risk of increasing susceptibility to seizures. * any person who has a history of drug abuse or a previous history of a neurological or psychiatric illness, or has a history of neurosurgical procedure is excluded as they may be at increased risk of epilepsy and data collected may be influenced by their condition. * patients on some prescription medications such as anti-depressants may be excluded as they may be at an increased risk of seizures. * anyone who is currently taking or who has taken anti-malarial treatment in the last 72 hours. * pregnant women are excluded as a precaution as there is no data on the effect on maternal cranial stimulation on the fetus. * any metallic implant in the neck, head, or eye and anyone with any implanted electrical devices would be excluded as there is a risk of heating with both tms and tdcs stimulation. * anyone with any metal implants or implantable device would be excluded as indicated by the mri safety screening form. people who suffer with claustrophobia as they are unable to tolerate the scanner. * patients who have had more than one stroke. patients who have had a stroke will also be excluded if they have limited communication in the form of aphasia or a history of dementia.

Keywords: tdcs stroke functional mri motor learning
covid-19 and social isolation and loneliness trial

Conditions: Social Isolation; Loneliness; Geriatric

Summary: social isolation and loneliness worsen older peoples' quality of life, risk of dementia, and contributes to 45,000 deaths/year in canada - as much as smoking. isolated people use the health care system more often, but have worse outcomes. effective, inexpensive interventions exist but unfortunately they have not been implemented in canada. we partnered with the australian developer of how r u?, an effective and feasible intervention that uses specially trained, older, hospital volunteers to provide peer support to combat isolation and loneliness in isolated older peers. little is known about older people's preferences for virtual care (telephone vs. video) nor their relative effectiveness. thus we will compare two ways of delivering how r u: telephone support and a tested, secure user-friendly video conferencing app, atouch away® to a common control arm. we also partnered with emergency medicine, family medicine, geriatrics and psychiatry to identify people who will benefit from peer support; and with volunteer services to recruit volunteers.


Eligibility criteria:
inclusion criteria: * any community-dwelling person 70 years of age and older receiving care from the ed, family medicine, or geriatric clinics at our two participating sites (msh and nygh) will be eligible. exclusion criteria: * age less than 70 years; communication problems (critically ill, unconscious, language barrier, speech impairment or otherwise unable to provide consent), or admission to a hospital for \> 72 hours. patients with severe cognitive impairment or those living in nursing homes who are dependent on others for their activity of daily living will be excluded. to target the intervention for older people with loneliness a baseline de jonge loneliness scores of 2.0 will be required for participation in the trial.

Keywords: loneliness social isolation emergency department geriatrics geriatric psychiatry family medicine randomized clinical trial